Choreo LLC Has $760,000 Stock Holdings in Danaher Co. (NYSE:DHR)

Choreo LLC boosted its holdings in shares of Danaher Co. (NYSE:DHR) by 174.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,284 shares of the conglomerate’s stock after buying an additional 2,089 shares during the period. Choreo LLC’s holdings in Danaher were worth $760,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of DHR. BKM Wealth Management LLC purchased a new position in Danaher during the 4th quarter valued at about $27,000. Wetzel Investment Advisors Inc. acquired a new stake in shares of Danaher during the fourth quarter worth approximately $29,000. OFI Invest Asset Management purchased a new position in Danaher during the third quarter valued at approximately $30,000. Rakuten Securities Inc. acquired a new position in Danaher in the 4th quarter valued at approximately $36,000. Finally, Financial Connections Group Inc. purchased a new stake in Danaher in the 4th quarter worth approximately $41,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Performance

Shares of DHR opened at $246.93 on Thursday. The company has a market capitalization of $182.90 billion, a PE ratio of 41.85, a price-to-earnings-growth ratio of 3.80 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. Danaher Co. has a one year low of $182.09 and a one year high of $259.00. The company’s fifty day moving average price is $248.71 and its 200 day moving average price is $231.90.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. During the same period in the previous year, the company posted $2.36 earnings per share. The firm’s revenue for the quarter was down 2.6% on a year-over-year basis. As a group, analysts expect that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, April 26th. Stockholders of record on Thursday, March 28th were issued a dividend of $0.27 per share. The ex-dividend date was Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. Danaher’s payout ratio is 18.31%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on DHR shares. Raymond James boosted their price target on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Citigroup upped their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Robert W. Baird lifted their price target on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. Barclays increased their price objective on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 24th. Finally, StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $267.31.

Insider Activity

In related news, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the transaction, the chief executive officer now owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Rainer Blair sold 47,175 shares of the stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the sale, the chief executive officer now owns 115,995 shares in the company, valued at $28,908,273.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Georgeann Couchara sold 2,622 shares of Danaher stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total value of $636,280.74. Following the sale, the senior vice president now directly owns 4,244 shares in the company, valued at $1,029,891.48. The disclosure for this sale can be found here. Over the last three months, insiders sold 106,565 shares of company stock valued at $26,641,364. 10.90% of the stock is owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.